




CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 29, 2005

Date

  
Shelley P.M. Fussey

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Rolf A. Brekken

Serial No.: 10/738,404

Filing Date: December 17, 2003

For: ANTI-VEGF ANTIBODY PRODRUG  
METHODS (As Amended)

Group Art Unit: 1642

Examiner: Joyce, C.

Atty. Dkt. No.: 3999.002587

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the documents listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection herewith. Even if an Official Action had been issued, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a foreign counterpart to the present application. The listed documents were published on-line on November 07, 2005 and November 14, 2005, respectively, and could not have been submitted before publication. The present statement is being filed within three months of the earliest on-line publication date, and is thus timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Examiner should contact the undersigned representative to discuss deduction from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/3999.002587.


Respectfully submitted  
PEREGRINE PHARMACEUTICALS, INC.  
Customer No. 000052101



Shelley P.M. Fussey, Ph.D.  
Reg. No. 39,458  
Agent for Applicants

5353 W. Alabama, Suite 306  
Houston, Texas, 77056  
(832) 886-5834

Date: November 29, 2005



Form PTO-1449 (modified)

Temp. Atty. Docket No.

3999.002587

Serial No.

10/738,404

## List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Thorpe *et al.*

Filing Date:

December 17, 2003

Group:

1642

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C169	Liang, <i>et al.</i> , "Cross-Species VEGF-Blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF," <i>J. Biol. Chem.</i> , <a href="http://www.jbc.org/cgi/doi/10.1074/jbc.org/M508199200">www.jbc.org/cgi/doi/10.1074/jbc.org/M508199200</a> , published on-line on November 7, 2005.
	C170	Meyer, <i>et al.</i> , "A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1," <i>J. Biol. Chem.</i> , <a href="http://www.jbc.org/cgi/doi/10.1074/jbc.org/M506454200">www.jbc.org/cgi/doi/10.1074/jbc.org/M506454200</a> , published on-line on November 14, 2005.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Information Disclosure Statement — PTO-1449 (Modified)